Statistics from Altmetric.com
We read with great interest the article by Chuang et al1 confirming proton pump inhibitor (PPI) use is associated with increased risk of cholecystitis.1 PPIs are a potent class of agents used to suppress gastric acid secretion and are among the most commonly prescribed medications globally.2 Presently, PPIs are routinely recommended for several GI disorders, including GORD, and as prophylaxis against peptic ulcer disease and GI bleeding in susceptible populations, such as individuals on dual antiplatelet therapy for secondary prevention of cardiovascular disease.3–5 In view of the large population of patients receiving PPI therapy, in many cases long-term therapy, ensuring the safety of PPI therapy is of considerable public health importance.6 Recently, PPIs have been reported to be associated with cholecystitis and might possibly be carcinogenic.1 However, no research has been conducted to investigate the association of PPIs with gallbladder cancer (GBC). Herein, a hospital-based case–control study was carried out in China to explore the association between PPIs and GBC risk.
A hospital-based case–control study was performed by enrolling 3030 …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.